Press release content from Business Wire. The AP news staff was not involved in its creation.
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
January 26, 2021 GMT
NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Jan 26, 2021--
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.